KUALA LUMPUR, Nov 1 -- SunGen Pharma LLC, a privately held specialty pharmaceutical company has received its eighth ANDA approval from the United States (US) Food and Drug Administration (FDA).
The eighth approved ANDA is for Lidocaine Ointment USP, five per cent, Package size: 1 ½ oz tube (35.44 g). This drug product is used for production of anesthesia of accessible mucous membranes of the oropharynx.
“These approvals represent one of many products being developed or co-developed by our company and with our partners globally,” said the company’s co-founder and co-chief executive officer, Dr Isaac Liu.
“Today, we have more than 40 active products in our pipeline and over 20 co-development, licensing, CMO and sales and marketing partnerships around the world.”
With annual sales of about US$60 million, the drug product is also useful as an anesthetic lubricant for intubation and for the temporary relief of pain associated with minor burns, including sunburn, abrasions of the skin and insect bites. (US$1 = RM4.17)
More information at https://sungenpharm.com.
-- BERNAMA
No comments:
Post a Comment